Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

The collective force of cancer research, outreach and care across the city of Oxford, translating discoveries into better care for cancer patients.

University of Oxford spinout doses first patient in oesophageal cancer vaccine trial

The trial has administered the first in human experimental cancer vaccine designed to help the immune system recognise and attack oesophageal cancer.

[Video] Cancer vaccines: responding to the early red flags

Making cancer curable is undoubtedly one of the biggest medical challenges we face. But what if we could actually prevent cancer from taking hold in the first place? That’s what Professor David Church and his team in the Centre for Human Genetics at the University of Oxford are investigating.

Dr Isabela Pedroza-Pacheco appointed new Against Breast Cancer Oriel College Research Fellow

Launched in 2018, the Against Breast Cancer Oriel Fellowship scheme funds outstanding scientists and clinicians conducting breast cancer research at the University of Oxford.

OxCODE funding scheme awards 2026

Congratulations to Ray DiNardi, Christiana Kartsonaki, Giuseppina Pisignano, Niyas Salam, Jie Yang and their collaborators who have been awarded funding in the seventh round of the OxCODE Funding Scheme.

Dr Lennard Lee recognised by Royal College of Physicians for pioneering AI cancer vaccine research

Lennard has received national recognition from the Royal College of Physicians (RCP) for leading research that is helping to accelerate the development of personalised cancer vaccines using artificial intelligence (AI) and advanced computing.

Study shows AI can be safely deployed in NHS prostate cancer diagnosis

Findings from the landmark Articulate Pro study have now been published, marking a major milestone for the use of artificial intelligence (AI) in NHS histopathology laboratories and demonstrating its potential to improve and standardise prostate cancer diagnosis.

Blood test could help doctors diagnose cancers faster, Oxford study suggests

Analysis of 2-year follow-up data from the NHS SYMPLIFY trial found a multi-cancer blood test could help speed up cancer diagnosis for some patients with symptoms, potentially reducing delays and directing people to the right investigations sooner.

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Oxford Cancer Immuno-Oncology Network hosts 2026 Annual Symposium

The Oxford Cancer Immuno-Oncology Network (OCION) hosted its 2026 Annual Symposium on Friday 19 June 2026 at the Mathematical Institute, University of Oxford.

[Blog] The importance of PPI in basic, preclinical, and laboratory-based research.

At the recent Oxford Cancer Pancreatic Clinical Academic Networking Day, held on Wednesday 3 June 2026, Julliet Lwiindi, Oxford Cancer’s Public Engagement and Involvement Officer, spoke to delegates about Patient and Public Involvement (PPI) and the important role it can play in research.

Professor KJ Patel awarded major European Research Council Advanced Grant

Professor Patel is one of fourteen researchers at the University of Oxford awarded Advanced Grants from the European Research Council (ERC), each worth up to €2.5 million over a period of five years.

New biomarker brings personalised Polθ inhibitor-radiotherapy treatment closer to the clinic

A new study led by Professor Geoff Higgins, in collaboration with Artios Pharma, has uncovered a genetic vulnerability that could help identify patients most likely to benefit from a promising radiotherapy combination treatment. Published in Science Advances, the research identifies loss of SHLD2 as a predictive biomarker for treatment with DNA polymerase theta (Polθ) inhibitors, an emerging class of DNA repair-targeted drugs.

Professor Adam Mead appointed as Director of Oxford Cancer

Oxford Cancer is delighted to announce the appointment of Professor Adam Mead as Director, joining Professors Mark Middleton and Tim Elliott in leading Oxford’s interdisciplinary cancer research community.

Oxford researchers hunt for hidden protein clues to prevent prostate cancer

A major new research programme, led by Professor Ruth Travis and Dr Karl Smith-Byrne and funded by Cancer Research UK, aims to uncover the biological causes of prostate cancer and identify ways to prevent the disease.

First trial of vaccine to prevent Lynch syndrome-associated cancers approved to start in Oxford

Phase 1 of the INTERCEPT-Lynch trial, which is funded by Moderna, sponsored by the University of Oxford and run by the University's Oncology Clinical Trials Office with support from Oxford Cancer, has received authorisation from the Medicines and Healthcare products Regulatory Agency and is expected to begin recruiting participants this summer.

Researchers uncover hidden mechanism behind a major cancer therapy target

Kennedy researchers have revealed how one of the immune system's most important regulatory pathways operates at the earliest moments of T cell activation, providing new insights that could help improve cancer immunotherapy.

Researchers uncover how cancer cells evade PARP inhibitor treatment

Research led by scientists at the University of Oxford and published today in Nature Cell Biology has uncovered a previously unknown mechanism that allows cancer cells to resist a widely used class of cancer drugs known as PARP inhibitors.

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.

Researchers gather to showcase advances in liver cancer research at 2nd annual OLivE symposium

Researchers and clinicians from across Oxford and beyond gathered at the Richard Doll Building, Old Road Campus, on Thursday 14 May for the Oxford Liver Cancer Centre of Excellence (OLivE) 2026 Symposium.

Dr Ejung Moon awarded MRC funding to target metastatic breast cancer’s “Achilles’ heel”

Dr Ejung Moon, Group Leader in the University of Oxford’s Department of Oncology, has been awarded funding from the Medical Research Council (MRC) to investigate a promising new strategy for treating metastatic breast cancer.

Load More